Updates are available Correction dated 2025-03-03
Click to view Correction: https://doi.org/10.1186/s40635-025-00723-1
-
Authors
Asgarpur, Golschan https://orcid.org/0000-0001-5328-2812
Weber, Franz https://orcid.org/0009-0002-4654-7434
Kiessling, Peggy https://orcid.org/0009-0009-4851-563X
Akbari, Nilufar https://orcid.org/0000-0002-3481-4956
Stroben, Fabian https://orcid.org/0009-0002-9878-6613
Kleikamp, Bernadette https://orcid.org/0009-0002-7750-6360
Kloft, Charlotte https://orcid.org/0000-0001-9344-8514
Treskatsch, Sascha https://orcid.org/0000-0002-0549-7680
Angermair, Stefan https://orcid.org/0000-0002-5440-6968
-
Funding
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Received: 28 October 2024
Accepted: 9 January 2025
First Online: 18 January 2025
Change Date: 3 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s40635-025-00723-1
Declarations
:
: The retrospective data analysis was approved by the ethics committee of the Charité—Universitätsmedizin Berlin (EA4/015/24) and registered in the German Clinical Trial Register (DRKS ID: 00034788). The retrospective data analysis adhered to the principles outlined in the Declaration of Helsinki. To gather patient information, Structured Query Language (SQL) inquiries were executed using the hospital’s electronic medical record system (COPRA System GmbH, Sasbachwalden, Germany, and SAP AG, Walldorf, Germany).
: Not applicable.
: ST received funding within an institutional research grant from Orion Pharma and Edwards as well as honoraria for lectures/workshops/advisory from Edwards, Orion Pharma, Amomed, CSents, Philips and Smith & Nephews outside the submitted work. SA received honoraria for lectures/advisory from Pfizer and Biotest. CK received research grants from an industry consortium (AbbVie Deutschland GmbH & Co. K.G., AstraZeneca, Boehringer Ingelheim Pharma GmbH & Co. KG., F. Hoffmann-La Roche Ltd., Merck KGaA, Novo Nordisk A/S and Sanofi) for the graduate research training program PharMetrX, from H2020-EU.3.1.3 (“FAIR”), all outside the submitted work. The other authors have declared that no competing interests exist. There are no other relationships/conditions/circumstances that present a potential conflict of interest. There are no patents, products in development or marketed products to declare. This does not alter our adherence to Critical Care policies on sharing data and materials. For any other aspects of the submitted work, no payment was received.
